Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection

Journal of Infectious Diseases

Volumn 190, Issue 10, 2004, Pages 1889-1892

  Pacanowski, Jérôme ^a   Develioglu, Leyla ^b   Kamga, Isabelle ^b   Sinet, Martine ^c   Desvarieux, Moïse ^d   Girard, Pierre Marie ^a   Hosmalin, Anne ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT COCHIN   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CORRELATION ANALYSIS; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MALE; PRIMARY INFECTION; PRIORITY JOURNAL; REBOUND; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL COUNT; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; VIREMIA;

EID: 8444227750     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425020     Document Type: Article

References (13)

1. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003;9:867-73.
2. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999;13:677-83.
3. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-14.
4. Siegal F, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.
5. Servet C, Zitvogel L, Hosmalin A. Dendritic cells in innate immune responses against HIV. Curr Mol Med 2002;2:739-56.
6. Steinman RM, Granelli-Piperno A, Pope M, et al. The interaction of immunodeficiency viruses with dendritic cells. Curr Top Microbiol Immunol 2003;276:1-30.
7. + dendritic cell numbers in primary HIV-1 infection. Blood 2001;98:3016-21.
8. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001;98:906-12.
9. Siegal FP, Fitzgerald-Bocarsly P, Holland BK, Shodell M. Interferon-α generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS 2001;15:1603-12.
10. Chehimi J, Campbell DE, Azzoni L, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002;168:4796-801.
11. Girard PM, Schneider V, Dehee A, et al. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. AIDS 2001;15:275-7.
12. Lacabaratz-Porret C, Urrutia A, Doisne JM, et al. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 2003;187:748-57.
13. + T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002;186:851-4.